nach oben

Current Urology Reports

Erschienen in:

01.10.2018 | Urothelial Cancer (S Daneshmand, Section Editor)

Enhanced Endoscopy in Bladder Cancer

verfasst von: Shane Pearce, Siamak Daneshmand

Erschienen in: Current Urology Reports | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Endoscopy coupled with targeted resections represents a cornerstone in the diagnosis, staging, and treatment of patients with bladder cancer. Direct visualization can be challenging and imprecise due to patient-, tumor-, and surgeon-specific factors. We will review contemporary endoscopic technologies and techniques used to improve our ability to safely identify and resect malignant lesions in patients with bladder cancer.

Recent Findings

Enhanced endoscopic imaging technology may improve detection rates for bladder cancer throughout the upper and lower urinary tract, which may lead to improvements in recurrence and progression rates for non-muscle invasive bladder cancer (NMIBC). New techniques including narrow-band imaging (NBI), photodynamic diagnosis (PDD), Storz Professional Image Enhancement System (SPIES), optical coherence tomography (OCT), and others have shown benefit and may further improve our ability to detect and stage bladder tumors.

Summary

Enhanced endoscopy technologies have already demonstrated value in improving the sensitivity of bladder cancer detection and early results suggest they may improve short- and long-term oncologic outcomes.

Siegel RL, Miller KD, Ahmedin J. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.CrossRefPubMed

Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21(18):1315–30.PubMedCrossRef

Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24(5):487–91.PubMedCrossRef

Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol. 2017;35(3):355–65.PubMedCrossRef

•• Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, et al. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Urol Oncol Semin Orig Investig. 2018; available from: http://www.sciencedirect.com/science/article/pii/S1078143918301352. The authors of this study report outcomes for blue light cystoscopy (BLC) from a multicenter registry including over 1600 lesions from 533 patients. BLC improved the detection rate by 12%b for papillary lesions and 43% for carcinoma in situ. Twenty-five percent of patients had lesions detected only on BLC and BLC findings changed management in 14% of cases.

Whitmore WF, Bush IM, Esquivel E. Tetracycline ultraviolet fluorescence in bladder carcinoma. Cancer. 1964;17:1528–32.PubMedCrossRef

Bryan RT, Billingham LJ, Wallace DMA. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008;101(6):702–5. discussion 705–706PubMedCrossRef

Scott WW. The development of the cystoscope. From “lichtleiter” to fiber optics. Investig Urol. 1969;6(6):657–61.

Samplaski MK, Jones JS. Two centuries of cystoscopy: the development of imaging, instrumentation and synergistic technologies. BJU Int. 2009;103(2):154–8.PubMedCrossRef

10.

Nicholson P. Problems encountered by early endoscopists. Urology. 1982;19(1):114–9.PubMedCrossRef

11.

Gow JG. Harold Hopkins and optical systems for urology--an appreciation. Urology. 1998;52(1):152–7.PubMedCrossRef

12.

Zainfeld D, Daneshmand S. Transurethral resection of bladder tumors: improving quality through new techniques and technologies. Curr Urol Rep. 2017;18(5):34.PubMedCrossRef

13.

Cockett WS, Cockett AT. The Hopkins rod-lens system and the Storz cold light illumination system. Urology. 1998;51(5A Suppl):1–2.PubMedCrossRef

14.

Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg. 1996;14(2):59–66.PubMedCrossRef

15.

Kriegmair M, Baumgartner R, Riesenberg R, Jocham D, Sassy T, Stocker S, et al. Photodynamic diagnosis following topical application of delta-aminolevulinic acid in a rat bladder tumor model. Investig Urol Berl Ger. 1994;5:85–7.

16.

Steinbach P, Kriegmair M, Baumgartner R, Hofstädter F, Knüchel R. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite 1s limited to urothelial cells. Urology. 1994;44(5):676–81.PubMedCrossRef

17.

Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44(6):836–41.PubMedCrossRef

18.

Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int. 2011;108(11):1703–7.PubMedCrossRef

19.

Lerner SP, Liu H, Wu M-F, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012;30(3):285–9.PubMedCrossRef

20.

Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–38.PubMedCrossRef

21.

• Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, et al. Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. J Urol. 2017;197(3 Pt 1):548–58. This recent meta-analysis and systematic review published in the Journal of Urology found that fluorescent cystoscopy was associated with a reduced recurrence risk at short-, intermediate-, and long-term follow-up. Fluorescent cystoscopy with HAL was also associated with a lower risk of disease progression (RR 0.51, 95% CI 0.28–0.96).PubMedCrossRef

22.

Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11(10):589–96.PubMedCrossRef

23.

Yuan H, Qiu J, Liu L, Zheng S, Yang L, Liu Z, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(9):e74142.PubMedPubMedCentralCrossRef

24.

Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015;15:566.PubMedPubMedCentralCrossRef

25.

Gallagher KM, Gray K, Anderson CH, Lee H, Stewart S, Donat R, et al. “Real-life experience”: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. World J Urol. 2017;35(12):1871–7.PubMedPubMedCentralCrossRef

26.

Kamat AM, Cookson M, Witjes JA, Stenzl A, Grossman HB. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer Amst Neth. 2016;2(2):273–8.CrossRef

27.

Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhöfer T, Schwentner C, et al. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol. 2015;33(10):1429–37.PubMedCrossRef

28.

Bach T, Bastian PJ, Blana A, Kaminsky A, Keller S, Knoll T, et al. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III. World J Urol. 2017 May;35(5):737–44.

29.

Pagliarulo V, Alba S, Gallone MF, Di Stasi S, Cormio L, Petitti T, et al. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy. J Endourol. 2017;31(4):405–11.

30.

Drăgoescu PO, Tudorache Ş, Drocaş AI, Mitroi G, Pănuş A, Drăgoescu NAM, et al. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. Romanian J Morphol Embryol Rev Roum Morphol Embryol. 2017;58(4):1279–83.

31.

• Kim SB, Yoon SG, Tae J, Kim JY, Shim JS, Kang SG, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy. Investig Clin Urol. 2018;59(2):98–105. This randomized, prospective trial found that NBI improves detection rates of bladder cancer, but found no difference in the 1-year recurrence rates.PubMedPubMedCentralCrossRef

32.

Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, et al. Comparison of white light, photodynamic diagnosis, and narrow-band imaging in detection of carcinoma in situ or flat dysplasia at transurethral resection of the bladder: the DaBlaCa-8 study. Urology. 2017;102:138–42.PubMedCrossRef

33.

•• Naito S, Algaba F, Babjuk M, Bryan RT, Sun Y-H, Valiquette L, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in Primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016;70(3):506–15. This manuscript reports the 1-year follow-up results of a randomized, single-blind, multicenter study conducted by the Clinical Research Office of the Endourological Society. They found that recurrence rates 12 months after TURBT with WL compared to NBI were not significantly different overall. They did find that NBI reduced the risk of recurrence in patients with low-risk bladder cancer.PubMedCrossRef

34.

Apfelbeck M, Grimm T, Kretschmer A, Buchner A, Schneevoigt B-S, Jokisch F, et al. Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient? Urol Oncol. 2017;35(10):602.e19–23.CrossRef

35.

•• Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase iii, comparative, multicenter study. J Urol. 2018;199(5):1158–65. This prospective, multicenter study demonstrated that office-based flexible blue light cystoscopy improves the detection of recurrent bladder cancer by 21% and is safe to use for disease surveillance.PubMedCrossRef

36.

Osman E, Alnaib Z, Kumar N. Photodynamic diagnosis in upper urinary tract urothelial carcinoma: a systematic review. Arab J Urol. 2017;15(2):100–9.PubMedPubMedCentralCrossRef

37.

Kata SG, Aboumarzouk OM, Zreik A, Somani B, Ahmad S, Nabi G, et al. Photodynamic diagnostic ureterorenoscopy: a valuable tool in the detection of upper urinary tract tumour. Photodiagn Photodyn Ther. 2016;13:255–60.CrossRef

38.

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.PubMedPubMedCentralCrossRef

39.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66(5):863–71.PubMedCrossRef

40.

Gakis G, Volkmer B, Qvick B, Marteau F, Stenzl A. Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder. Urol Ausg A. 2018;

41.

Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15;121(2):169–78.PubMedCrossRef

42.

Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One. 2017;12(2):e0170819.PubMedPubMedCentralCrossRef

43.

Kang W, Cui Z, Chen Q, Zhang D, Zhang H, Jin X. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017 Apr 4;8(14):23880–90.PubMed

44.

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.PubMedCrossRef

45.

Emiliani E, Talso M, Baghdadi M, Barreiro A, Orosa A, Serviàn P, et al. Evaluation of the spies TM modalities image quality. Int Braz J Urol Off J Braz Soc Urol. 2017;43(3):476–80.CrossRef

46.

Kamphuis GM, de Bruin DM, Brandt MJ, Knoll T, Conort P, Lapini A, et al. Comparing image perception of bladder tumors in four different Storz Professional Image Enhancement System modalities using the íSPIES app. J Endourol. 2016;30(5):602–8.PubMedCrossRef

47.

Gravas S, Stenzl A. The Storz professional image enhancement system (SPIES) nonmuscle-invasive bladder cancer study:a multicenter international randomized controlled study. J Endourol. 2014;28(11):1254–5.PubMed

48.

Lurie KL, Smith GT, Khan SA, Liao JC, Ellerbee AK. Three-dimensional, distendable bladder phantom for optical coherence tomography and white light cystoscopy. J Biomed Opt. 2014;19(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951584/

49.

Ren H, Waltzer WC, Bhalla R, Liu J, Yuan Z, Lee CSD, et al. Diagnosis of bladder cancer with microelectromechanical systems-based cystoscopic optical coherence tomography. Urology. 2009;74(6):1351–7.PubMedCrossRef

50.

Manyak MJ, Gladkova ND, Makari JH, Schwartz AM, Zagaynova EV, Zolfaghari L, et al. Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. J Endourol. 2005;19(5):570–4.PubMedCrossRef

51.

Lingley-Papadopoulos CA, Loew MH, Manyak MJ, Zara JM. Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis. J Biomed Opt. 2008;13(2):024003.PubMedCrossRef

52.

Goh AC, Tresser NJ, Shen SS, Lerner SP. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008;72(1):133–7.PubMedCrossRef

53.

Ren H, Yuan Z, Waltzer W, Shroyer K, Pan Y. Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. J Urol. 2010;184(4):1499–506.PubMedCrossRef

54.

Ren H, Park KC, Pan R, Waltzer WC, Shroyer KR, Pan Y. Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography. J Urol. 2012;187(3):1063–70.PubMedCrossRef

55.

Huang J, Ma X, Zhang L, Jia H, Wang F. Diagnostic accuracy of optical coherence tomography in bladder cancer patients: a systematic review and meta-analysis. Mol Clin Oncol. 2018;8(4):609–12.

56.

Schmidbauer J, Remzi M, Klatte T, Waldert M, Mauermann J, Susani M, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol. 2009;56(6):914–9.PubMedCrossRef

57.

Lingley-Papadopoulos CA, Loew MH, Zara JM. Wavelet analysis enables system-independent texture analysis of optical coherence tomography images. J Biomed Opt. 2009;14(4):044010.PubMedCrossRef

58.

Marvdashti T, Duan L, Aasi SZ, Tang JY, Ellerbee Bowden AK. Classification of basal cell carcinoma in human skin using machine learning and quantitative features captured by polarization sensitive optical coherence tomography. Biomed Opt Express. 2016;7(9):3721–35.PubMedPubMedCentralCrossRef

59.

Canto MI, Anandasabapathy S, Brugge W, Falk GW, Dunbar KB, Zhang Z, et al. In vivo endomicroscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc. 2014;79(2):211–21.PubMedCrossRef

60.

Marien A, Rock A, Maadarani KE, Francois C, Gosset P, Mauroy B, et al. Urothelial tumors and dual-band imaging: a new concept in confocal laser endomicroscopy. J Endourol. 2017;31(5):538–44.PubMedCrossRef

61.

Naya Y, Takaha N, Okubo T, Shiota K, Hayashi I, Mori M, et al. Probe-based confocal laser endomicroscopy using acrinol as a novel dye can be used to observe Cancer nuclei of bladder carcinoma in situ. J Endourol Case Rep. 2018;4(1):25–7.PubMedPubMedCentralCrossRef

62.

Bui D, Mach KE, Zlatev DV, Rouse RV, Leppert JT, Liao JC. A pilot study of in vivo confocal laser endomicroscopy of upper tract Urothelial carcinoma. J Endourol. 2015;29(12):1418–23.PubMedPubMedCentralCrossRef

63.

Liem EI, Freund JE, Baard J, de Bruin DM, Laguna Pes MP, Savci-Heijink CD, et al. Confocal laser endomicroscopy for the diagnosis of urothelial carcinoma in the bladder and the upper urinary tract: protocols for two prospective explorative studies. JMIR Res Protoc. 2018;7(2):e34.PubMedPubMedCentralCrossRef

Titel: Enhanced Endoscopy in Bladder Cancer
verfasst von: Shane Pearce
Siamak Daneshmand
Publikationsdatum: 01.10.2018
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 10/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-018-0833-9

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma

Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation

Imaging Protocols for Active Surveillance in Renal Cell Carcinoma

Approaches to Eliminate Radiation Exposure in the Management of Pediatric Urolithiasis